SOURCE: CDEX Inc.

December 20, 2007 09:34 ET

CDEX Inc. Meets Medication Signature Library Goal for ValiMed™ Ahead of Schedule

TUCSON, AZ--(Marketwire - December 20, 2007) - CDEX Inc. (OTCBB: CEXI) announces the addition of 43 new signatures to its ValiMed™ Medication Signature Library, bringing the Library's total to 150 signatures. (A signature is an electronic fingerprint of a medication at a given concentration in a prescribed diluent.) "On June 7, 2007, we announced the goal of expanding our Signature Library from 70 to 150 by the end of 2007," said Malcolm Philips, CDEX CEO. "Working with our expanding group of Clients, we met that goal, ahead of schedule! And we will continue to expand the Library as directed by the national and international markets."

ValiMed™ uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to its expected CDEX Library signature and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation.

"When the CDEX Team develops a ValiMed signature, we test over 400 separate samples of the medication mixture," said Carlos Alvarez, CDEX's Manager of Production and Technical Support. "Then each potential signature is scrubbed though a number of practical and medical gates and sent through a concentration/dilution study before being placed in the CDEX Library for use by our clients. We know that the accuracy of each signature is important to our clients and the patients that they serve -- and it is critical that we get it right."

For a complete list of the ValiMed Medication Signature Library see www.ValiMed.com or www.CDEX-Inc.com.

About CDEX Inc.

CDEX, a technology development company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the Meth Scanner™ are CDEX solutions for the healthcare and security markets. Corporate headquarters and R&D facilities are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Stuart Poteet (spoteet@cdex-inc.com) at 520.745.5172 X 210 or 202.

ANY NON-HISTORICAL STATEMENTS ARE FORWARD-LOOKING, AS DEFINED IN FEDERAL SECURITIES LAWS, AND GENERALLY CAN BE IDENTIFIED BY WORDS SUCH AS "EXPECTS," "PLANS," "MAY," "ANTICIPATES," "BELIEVES," "SHOULD," "INTENDS," "ESTIMATES," AND OTHER SIMILAR WORDS. THESE STATEMENTS POSE RISKS AND UNCERTAINTIES THAT CANNOT BE PREDICTED OR QUANTIFIED AND, CONSEQUENTLY, ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED. SUCH RISKS AND UNCERTAINTIES INCLUDE, WITHOUT LIMITATION, THE EFFECTIVENESS, PROFITABILITY AND MARKETABILITY OF PRODUCTS, THE PROTECTION OF INTELLECTUAL PROPERTY AND PROPRIETARY INFORMATION, AND OTHER RISKS DETAILED FROM TIME-TO-TIME IN FILINGS WITH THE SEC. THERE IS NO OBLIGATION TO PUBLICLY UPDATE ANY FORWARD-LOOKING STATEMENTS.

Contact Information